{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T08:11:29Z","timestamp":1762762289798,"version":"3.40.2"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,24]]},"DOI":"10.7759\/cureus.81081","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T14:41:44Z","timestamp":1742827304000},"source":"Crossref","is-referenced-by-count":1,"title":["Influence of PSMB6 and PSMB9 Genetic Polymorphisms on Bortezomib-Based Therapy Response in Newly Diagnosed Multiple Myeloma"],"prefix":"10.7759","author":[{"given":"Nidhi","family":"Sood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdoul","family":"Hamide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biswajit","family":"Dubashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathaiyan","family":"Jayanthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.K.","family":"Munirajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Multiple myeloma","author":"Albagoush SA","year":"2024","unstructured":"Albagoush SA, Shumway C, Azevedo AM. Multiple myeloma. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar SV","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022, 97:1086-107. 10.1002\/ajh.26590","journal-title":"Am J Hematol"},{"key":"ref3","article-title":"Harrison's Manual of Medicine: 16th Edition","author":"Kasper D","year":"2005","unstructured":"Kasper D, Braunwald E, Fauci A. Harrison's Manual of Medicine: 16th Edition. McGraw-Hill Education, Maidenhead, England; 2005."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2019.02.010","article-title":"Distribution of multiple myeloma in India: heterogeneity in incidence across age, sex and geography","volume":"59","author":"Bora K","year":"2019","unstructured":"Bora K. Distribution of multiple myeloma in India: heterogeneity in incidence across age, sex and geography. Cancer Epidemiol. 2019, 59:215-20. 10.1016\/j.canep.2019.02.010","journal-title":"Cancer Epidemiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0141","article-title":"Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment","volume":"25","author":"Ludwig H","year":"2020","unstructured":"Ludwig H, Novis Durie S, Meckl A, Hinke A, Durie B. Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment. Oncologist. 2020, 25:e1406-13. 10.1634\/theoncologist.2020-0141","journal-title":"Oncologist"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2183\/pjab.85.12","article-title":"The proteasome: overview of structure and functions","volume":"85","author":"Tanaka K","year":"2009","unstructured":"Tanaka K. The proteasome: overview of structure and functions. Proc Jpn Acad Ser B Phys Biol Sci. 2009, 85:12-36. 10.2183\/pjab.85.12","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.8-6-508","article-title":"Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy","volume":"8","author":"Kane RC","year":"2003","unstructured":"Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist. 2003, 8:508-13. 10.1634\/theoncologist.8-6-508","journal-title":"Oncologist"},{"key":"ref8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcsup.2004.04.004","article-title":"Bortezomib in multiple myeloma: treatment approach and outcomes","volume":"2","author":"Harousseau JL","year":"2004","unstructured":"Harousseau JL. Bortezomib in multiple myeloma: treatment approach and outcomes. Eur J Cancer Suppl. 2004, 2:12-17.","journal-title":"Eur J Cancer Suppl"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13040695","article-title":"Bortezomib pharmacogenetic biomarkers for the treatment of multiple myeloma: review and future perspectives","volume":"13","author":"Sanz-Solas A","year":"2023","unstructured":"Sanz-Solas A, Labrador J, Alcaraz R, Cuevas B, Vinuesa R, Cuevas MV, Saiz-Rodr\u00edguez M. Bortezomib pharmacogenetic biomarkers for the treatment of multiple myeloma: review and future perspectives. J Pers Med. 2023, 13:10.3390\/jpm13040695","journal-title":"J Pers Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355081","article-title":"Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"118","author":"Moreau P","year":"2011","unstructured":"Moreau P, Avet-Loiseau H, Facon T, et al.. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood. 2011, 118:5752-8; quiz 5982. 10.1182\/blood-2011-05-355081","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.26","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial","volume":"23","author":"Reeder CB","year":"2009","unstructured":"Reeder CB, Reece DE, Kukreti V, et al.. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia. 2009, 23:1337-41. 10.1038\/leu.2009.26","journal-title":"Leukemia"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.621.621","article-title":"Novel three- and four-drug combination regimens of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide, for previously untreated multiple myeloma: Results from the multi-center, randomized, phase 2 EVOLUTION study","volume":"116","author":"Kumar S","year":"2010","unstructured":"Kumar S, Flinn IW, Richardson PG, et al.. Novel three- and four-drug combination regimens of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide, for previously untreated multiple myeloma: Results from the multi-center, randomized, phase 2 EVOLUTION study. Blood. 2010, 116:621.","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2174\/1389450121666200525004714","article-title":"The ubiquitin-proteasome pathway and resistance mechanisms developed against the proteasomal inhibitors in cancer cells","volume":"21","author":"Yerlikaya A","year":"2020","unstructured":"Yerlikaya A, Kanbur E. The ubiquitin-proteasome pathway and resistance mechanisms developed against the proteasomal inhibitors in cancer cells. Curr Drug Targets. 2020, 21:1313-25. 10.2174\/1389450121666200525004714","journal-title":"Curr Drug Targets"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-19-1026","article-title":"Proteasome subunits differentially control myeloma cell viability and proteasome inhibitor sensitivity","volume":"18","author":"Shi CX","year":"2020","unstructured":"Shi CX, Zhu YX, Bruins LA, Bonolo de Campos C, Stewart W, Braggio E, Stewart AK. Proteasome subunits differentially control myeloma cell viability and proteasome inhibitor sensitivity. Mol Cancer Res. 2020, 18:1453-64. 10.1158\/1541-7786.MCR-19-1026","journal-title":"Mol Cancer Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/biom11010060","article-title":"The ubiquitin-proteasome system in immune cells","volume":"11","author":"\u00c7etin G","year":"2021","unstructured":"\u00c7etin G, Klafack S, Studencka-Turski M, Kr\u00fcger E, Ebstein F. The ubiquitin-proteasome system in immune cells. Biomolecules. 2021, 11:60. 10.3390\/biom11010060","journal-title":"Biomolecules"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1086\/510257","article-title":"Exact tests of Hardy-Weinberg equilibrium and homogeneity of disequilibrium across strata","volume":"79","author":"Schaid DJ","year":"2006","unstructured":"Schaid DJ, Batzler AJ, Jenkins GD, Hildebrandt MA. Exact tests of Hardy-Weinberg equilibrium and homogeneity of disequilibrium across strata. Am J Hum Genet. 2006, 79:1071-80. 10.1086\/510257","journal-title":"Am J Hum Genet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie BG","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, et al.. International uniform response criteria for multiple myeloma. Leukemia. 2006, 20:1467-73. 10.1038\/sj.leu.2404284","journal-title":"Leukemia"},{"key":"ref18","unstructured":"National Center for Biotechnology Information. Accessed. February 7, 2024: https:\/\/www.ncbi.nlm.nih.gov\/snp\/\/."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"175","author":"Yong K","year":"2016","unstructured":"Yong K, Delforge M, Driessen C, et al.. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016, 175:252-64. 10.1111\/bjh.14213","journal-title":"Br J Haematol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez127","article-title":"Testing and management for monoclonal gammopathy of uncertain significance and myeloma patients presenting with osteoporosis and fragility fractures","volume":"58","author":"Nador G","year":"2019","unstructured":"Nador G, Ramasamy K, Panitsas F, Pratt G, Sadler R, Javaid MK. Testing and management for monoclonal gammopathy of uncertain significance and myeloma patients presenting with osteoporosis and fragility fractures. Rheumatology (Oxford). 2019, 58:1142-53. 10.1093\/rheumatology\/kez127","journal-title":"Rheumatology (Oxford)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-052759","article-title":"Clinical features and diagnosis of multiple myeloma: a population-based cohort study in primary care","volume":"11","author":"Seesaghur A","year":"2021","unstructured":"Seesaghur A, Petruski-Ivleva N, Banks VL, Wang JR, Abbasi A, Neasham D, Ramasamy K. Clinical features and diagnosis of multiple myeloma: a population-based cohort study in primary care. BMJ Open. 2021, 11:e052759. 10.1136\/bmjopen-2021-052759","journal-title":"BMJ Open"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-426924","article-title":"Sequence analysis of \u03b2-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone","volume":"120","author":"Lichter DI","year":"2012","unstructured":"Lichter DI, Danaee H, Pickard MD, et al.. Sequence analysis of \u03b2-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. Blood. 2012, 120:4513-16. 10.1182\/blood-2012-05-426924","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2013.14.11.6399","article-title":"Association of an LMP2 polymorphism with acute myeloid leukemia and multiple myeloma","volume":"14","author":"Ozbas-Gerceker F","year":"2013","unstructured":"Ozbas-Gerceker F, Bozman N, Kok S, Pehlivan M, Yilmaz M, Pehlivan S, Oguzkan-Balci S. Association of an LMP2 polymorphism with acute myeloid leukemia and multiple myeloma. Asian Pac J Cancer Prev. 2013, 14:6399-402. 10.7314\/apjcp.2013.14.11.6399","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13235949","article-title":"Genome instability in multiple myeloma: facts and factors","volume":"13","author":"Aksenova AY","year":"2021","unstructured":"Aksenova AY, Zhuk AS, Lada AG, et al.. Genome instability in multiple myeloma: facts and factors. Cancers (Basel). 2021, 13:5949. 10.3390\/cancers13235949","journal-title":"Cancers (Basel)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/life12060812","article-title":"Review of multiple myeloma genetics including effects on prognosis, response to treatment, and diagnostic workup","volume":"12","author":"Wiedmeier-Nutor JE","year":"2022","unstructured":"Wiedmeier-Nutor JE, Bergsagel PL. Review of multiple myeloma genetics including effects on prognosis, response to treatment, and diagnostic workup. Life (Basel). 2022, 12:812. 10.3390\/life12060812","journal-title":"Life (Basel)"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2018.1479637","article-title":"Optimizing therapy in bortezomib-exposed patients with multiple myeloma","volume":"11","author":"Migkou M","year":"2018","unstructured":"Migkou M, Gavriatopoulou M, Terpos E, Dimopoulos MA. Optimizing therapy in bortezomib-exposed patients with multiple myeloma. Expert Rev Hematol. 2018, 11:463-9. 10.1080\/17474086.2018.1479637","journal-title":"Expert Rev Hematol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.17179\/excli2022-5653","article-title":"Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications","volume":"22","author":"Alwahsh M","year":"2023","unstructured":"Alwahsh M, Farhat J, Talhouni S, Hamadneh L, Hergenr\u00f6der R. Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications. EXCLI J. 2023, 22:146-68. 10.17179\/excli2022-5653","journal-title":"EXCLI J"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2174\/156800911794519752","article-title":"Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives","volume":"11","author":"Chen D","year":"2011","unstructured":"Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets. 2011, 11:239-53. 10.2174\/156800911794519752","journal-title":"Curr Cancer Drug Targets"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-020-01281-8","article-title":"Ubiquitin-proteasome system (UPS) as a target for anticancer treatment","volume":"43","author":"Park J","year":"2020","unstructured":"Park J, Cho J, Song EJ. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment. Arch Pharm Res. 2020, 43:1144-61. 10.1007\/s12272-020-01281-8","journal-title":"Arch Pharm Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100971","article-title":"Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML","volume":"56","author":"Drula R","year":"2022","unstructured":"Drula R, Iluta S, Gulei D, et al.. Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML. Blood Rev. 2022, 56:100971. 10.1016\/j.blre.2022.100971","journal-title":"Blood Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/319954-influence-of-psmb6-and-psmb9-genetic-polymorphisms-on-bortezomib-based-therapy-response-in-newly-diagnosed-multiple-myeloma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T14:42:01Z","timestamp":1742827321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/319954-influence-of-psmb6-and-psmb9-genetic-polymorphisms-on-bortezomib-based-therapy-response-in-newly-diagnosed-multiple-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.81081","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,24]]}}}